MK-677 (ibutamoren) is an orally bioavailable, non-peptide GHSR-1a agonist with a long half-life (~24 hours); ipamorelin is an injectable pentapeptide with a short half-life (~2 hours) and greater receptor selectivity for isolated pulsatile GH research.
Research reference only — all information on this page summarises peer-reviewed scientific literature and does not constitute medical advice. View full compound profiles: MK-677 · Ipamorelin
Mechanism Comparison
Both MK-677 and ipamorelin activate GHSR-1a, triggering pituitary GH release. MK-677 is a small-molecule spiropiperidine compound — the only orally bioavailable GHSR-1a agonist in the published GHS literature — with ~62% oral bioavailability and a half-life of approximately 24 hours, producing sustained (non-pulsatile) GH and IGF-1 elevation. Ipamorelin is a peptide that requires subcutaneous injection but provides selective, shorter-lived GH pulses with minimal cortisol or prolactin co-stimulation.
Side-by-Side Attributes
| Attribute | MK-677 | Ipamorelin |
|---|---|---|
| Chemical class | Non-peptide spiropiperidine (small molecule) | Pentapeptide |
| Administration route | Oral (capsule/tablet) | Subcutaneous injection |
| Oral bioavailability | ~62% | Not orally bioavailable (peptide) |
| Half-life | ~24 hours | ~2 hours |
| GH pattern produced | Sustained (non-pulsatile) elevation | Pulsatile (short-lived peaks) |
| IGF-1 effect in research | Sustained elevation (continuous GHSR-1a activation) | Pulsatile; less sustained at standard dosing |
| Cortisol / prolactin effect | Modest; also increases appetite (ghrelin-like) | Minimal — most selective GHS studied |
| Appetite stimulation | Significant (ghrelin mimicry) | Minimal |
| Regulatory status | Investigational (no FDA approval); 503A restricted | Investigational; 503A Cat 2 restricted |
Key Research Points
- 1MK-677's oral bioavailability is its primary research advantage — it enables non-invasive dosing protocols in studies where injection compliance or stress-response confounds are methodological concerns.
- 2The long half-life of MK-677 (~24 h) produces a sustained, non-pulsatile IGF-1 elevation in research subjects — useful for studies examining tonic IGF-1 effects, but a confound when studying pulsatile GH axis biology.
- 3Ipamorelin is preferred when researchers need isolated, discrete GH pulses — its ~2-hour half-life produces clean pharmacokinetic windows and its selectivity minimises cortisol/prolactin confounds.
- 4MK-677 produces significant appetite stimulation via ghrelin receptor activation — an experimental confound in metabolic or caloric intake studies that must be controlled, and a variable absent with ipamorelin.
- 5Both compounds are WADA-listed or under monitoring frameworks for competitive sport research contexts; MK-677 appears on the WADA S2 list as a non-approved GHSR agonist.
Frequently Asked Questions
What is the main advantage of MK-677 over ipamorelin in research protocols?
MK-677 is the only orally bioavailable GHSR-1a agonist in the published research literature — it can be administered by capsule without injection, eliminating the injection-stress confound and improving compliance in longer-duration studies. Its ~24-hour half-life also enables once-daily dosing in chronic IGF-1 elevation protocols. Ipamorelin requires subcutaneous injection and has a ~2-hour half-life, requiring more frequent administration for sustained GH axis stimulation.
Why would a researcher choose ipamorelin over MK-677?
Ipamorelin is preferred when research requires discrete pulsatile GH events with minimal off-target receptor activity. Its selectivity — minimal cortisol, ACTH, prolactin, and appetite stimulation — makes it the cleaner experimental tool for isolating GH-specific effects. MK-677's sustained GH/IGF-1 elevation blurs pulsatile GH dynamics, and its appetite stimulation creates a caloric intake confound in metabolic studies. For protocols studying GH pulse amplitude, frequency, or acute GH-mediated tissue effects, ipamorelin's short half-life is a feature, not a limitation.
Does MK-677 increase IGF-1 levels in published research?
Yes — sustained IGF-1 elevation is one of the most consistently reported findings in MK-677 research. Multiple Phase 2 trials demonstrated dose-dependent IGF-1 increases with once-daily oral MK-677 administration. The Nass et al. study (Ann Intern Med, 2008) in healthy older adults reported significant IGF-1 elevation sustained over the 2-year treatment period. IGF-1 elevation is considered the pharmacodynamic marker of GHSR-1a agonism for sustained protocols in the research literature.
Deep Dive
For extended mechanism analysis, trial data, and regulatory context, see the full research article:
MK-677 vs Ipamorelin: Oral GH Secretagogue Research Comparison →Full compound profile
MK-677
Full compound profile
Ipamorelin